MetaCap

Bionano Genomics (BNGO) vs EyePoint (EYPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bionano Genomics (BNGO) has outperformed EyePoint (EYPT) over the past year, losing 49.2% versus a loss of 98.3%. Over five years, EYPT leads with a -98.6% price change compared with -100.0% for BNGO. EyePoint is the larger company by market cap ($26.6 million vs $11.5 million), about 2.3 times the size, while Bionano Genomics is growing revenue faster (-7.4% vs -27.5%).

Bionano Genomics converts more of its revenue into profit, with a net margin of -92.6% versus -739.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNGO-49.25%EYPT-98.29%
+45%-30%-105%
Nov 21, 20251 yearNov 20, 2026
BNGO-99.97%EYPT-98.64%
+75%-16%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNGO versus EYPT key metrics
MetricBNGOEYPT
Share price$0.8222$0.2342
Market cap$11.50M$26.65M
1-day change-7.11%-11.36%
YTD return-46.26%-98.72%
1-year return-49.25%-98.29%
5-year return-99.97%-98.58%
EPS (TTM)$-1.96$-3.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$28.51M$31.37M
Revenue growth (YoY)-7.37%-27.50%
Net income (latest FY)$-26.39M$-231.96M
Gross margin46.25%—
Operating margin-116.95%-775.98%
Net margin-92.59%-739.42%
52-week high$2.23$19.11
52-week low$0.81$0.2277
Distance from 52-week high-63.13%-98.77%
Analyst consensusnonebuy
Avg. price target upside+508.12%+10963.19%
Average volume979.44K8.37M
Shares outstanding13.99M113.78M
Employees95214
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EyePoint is about 2.3 times larger than Bionano Genomics by market value ($26.65M vs $11.50M).
  • BNGO has outperformed EYPT by 49.0 percentage points over the past year.
  • Bionano Genomics is more profitable, keeping -92.6 cents of every revenue dollar as net income versus -739.4 cents for EyePoint.
  • Bionano Genomics grew revenue faster in its latest fiscal year (-7.37% vs -27.50%).

About Bionano Genomics

BNGO stock →

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.

Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees

About EyePoint

EYPT stock →

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.

Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees

BNGO vs EYPT FAQ

Which is bigger, Bionano Genomics or EyePoint?

EyePoint (EYPT) is larger, with a market capitalization of $26.65M compared with $11.50M for Bionano Genomics (BNGO).

Which stock has performed better over the past year, BNGO or EYPT?

BNGO returned -49.25% over the past 12 months, compared with -98.29% for EYPT (price return, excluding dividends). Past performance does not predict future results.

Are Bionano Genomics and EyePoint in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons